Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

TOP - February 2013 VOL 6, NO 1

Several studies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) found that a regimen that combines bendamustine with rituximab (B-R) may result in superior outcomes compared with the current standard of care, rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) or rituximab plus cyclophosphamide/vincristine/prednisone (R-CVP), in patients with non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL).
A wealth of abstracts were presented at the 54th Annual Meeting of the American Society of Hematology (ASH), held in Atlanta, Georgia, on December 8-11, 2012. More than 18,000 hematologists and other healthcare professionals from around the world gathered to discuss the latest clinical developments in research, therapies, and practice strategies. Below are some of the highlights from that meeting.
TOP - February 2013 VOL 6, NO 1 published on March 4, 2013 in Breast Cancer
For preventing bone metastases in women with early breast cancer, the current body of evidence does not support the use of osteoclast-targeting agents, ie, bisphosphonates, according to Julie Gralow, MD, director of Breast Medical Oncology at the Fred Hutchinson Cancer Research Center in Seattle, Washington.
TOP - February 2013 VOL 6, NO 1 published on March 4, 2013 in Supportive Care
Bayesian networks based on single nucleotide polymorphisms (SNPs), developed from saliva-sourced DNA, can be used to predict the occurrence of adverse effects associated with chemotherapy.
Page 3 of 3
Results 21 - 24 of 24